Srdan Dragovic

Srdan Dragovic has significant work experience in the field of biomedical research. Srdan is currently employed as a Senior Research Scientist at Oncoinvent AS since May 2022. Prior to that, they worked as a Postdoctoral Fellow at the Ragon Institute of MGH, MIT, and Harvard from May 2019 to December 2021. Before that, they served as a Senior Postdoctoral Fellow at Yale University School of Medicine from February 2012 to December 2018. Srdan also has experience as a Graduate Student and defended their PhD thesis at Vanderbilt University Department of Microbiology and Immunology from August 2005 to December 2011. During this time, they published groundbreaking research on the negative regulation of CD4 T cell activation and effector function, leading to potential advancements in T cell-based vaccine design against tumors and pathogens. Srdan utilized molecular, cellular immunology, and biochemical approaches in their studies.

Srdan Dragovic's education history begins with their Bachelor of Science degree in Pharmacy and Medical Biochemistry, which they obtained from the University of Belgrade - Faculty of Pharmacy between the years 1997 and 2003. Srdan then pursued further studies at Vanderbilt University, where they earned a Doctor of Philosophy (PhD) in Microbiology and Immunology between 2005 and 2011.

After completing their PhD, Dragovic joined Yale University and its School of Medicine in 2012 as an Associate Research Scientist in the field of Infectious Diseases. Srdan held this position until 2018, concurrently being affiliated with Yale University during this time. Subsequently, Dragovic moved on to the Ragon Institute of MGH, MIT, and Harvard, where they worked as a Postdoctoral Researcher from 2019 to 2022.

The provided information does not specify the field of study for Dragovic's position at Yale University School of Medicine and the Ragon Institute of MGH, MIT, and Harvard.